In order to identify the role of CRBP-1 in cancer cell chemotherapy resistance, the first-line treatment drug for advanced HCC—sorafenib was used to treat CRBP-1 overexpressed PLC/PRF/5 cells. Here, RBP1 is linked to hepatocellular carcinoma.